13Short and long-term PPI treatment for GERD. Do we need more-potent anti-secretory drugs?
Introduction
According to the Montreal definition, gastroesophageal reflux disease (GERD) is a condition that develops when reflux of the stomach contents into the esophagus causes troublesome symptoms and/or complications [1]. GERD impacts quality of life (HR-QOL) and reduces work productivity [2], [3], [4]. Hence, moderate reflux symptoms occurring more than once a week impair HRQOL and can be considered as GERD, irrespective of the presence or absence of mucosal breaks at endoscopy [5]. Because the reflux of the acidic gastric content into the esophagus plays a major role in the pathogenesis of GERD symptoms and erosive esophagitis (EE) lesions, acid suppression is currently the most-effective drug therapeutic approach. During the last two decades, the superiority of proton pump inhibitors (PPIs) over other drugs (antacids, prokinetics and H2-receptor antagonists) has been established beyond doubt by many pharmacological studies and large clinical trials [6], [7]. PPIs are now considered as the mainstay of anti-reflux medical therapy and are extensively prescribed, not only by gastroenterologists and GPs but also by non-GI specialists such as cardiologists, pneumologists or ENT specialists. Due to the high prevalence of GERD, they represent a huge economic burden, far beyond the treatment of the most-frequent malignancies [8]. However, despite the unprecedented commercial success of this class of drugs, there remain some unmet needs in GERD therapy. For example, it has become increasingly evident that there are subgroups of patients less- (or un-) responsive to PPIs, such as those with so-called non-erosive reflux disease (NERD) or atypical manifestations. Regarding safety, although most studies on short/long-term PPI use have provided reassuring data, recent reports have highlighted potential side effects or drug–drug interference.
GERD treatment can be subdivided into acute treatment, during which healing of esophagitis lesions and/or symptom control is the aim, and a maintenance phase during which the maintenance of healing and/or symptom control should be achieved. In this chapter, we have chosen to review recent data (published after 2000) on PPI efficacy and to discuss more extensively the long-term strategies available for GERD treatment, as well as the shortcomings and limitations of current PPIs. For older studies, the reader is referred to a previous issue of Best Practice in Gastroenterology [9], [10].
Section snippets
PPI pharmacology: what is new and what is relevant to the clinic?
Five PPI molecules are available on the market in most developed countries, omeprazole, lansoprazole, pantoprazole, rabeprazole and the more-recently developed S-enantiomer of omeprazole, esomeprazole. Some special formulations are also available, such as the lansoprazole disintegrated tablets which may be more convenient to some patients [11].
All current PPIs are substituted benzimidazoles which interact with gastric H+/K+ ATPase (the proton pump), the enzyme constituting the final step in the
The objectives
The objectives of short-term PPI therapy are rapid symptom relief and the healing of mucosal breaks in the case of EE. Most clinical trials have evaluated efficacy after 4 or 8 weeks of daily PPI administration at different doses and dosing frequencies (usually once daily).
Esophageal lesion healing is the most objective outcome measure and, due to the better grading system offered by the Los Angeles classification, results from different studies can be more-reliably compared than in the past.
Long-term management with PPI therapy
GERD is a chronic, relapsing disease. Once healing of mucosal breaks and sufficient symptom relief have been achieved by initial therapy, the main goals of long-term management are to maintain symptom control and prevent lesion recurrence, allowing a return to a nearly-normal quality of life. Recent cohort studies have shown that GERD can progress with time [59], [60] and in some cases complications develop, making prevention of these complications another important objective. In many patients,
Atypical symptoms
The degree of association and causal relationship with reflux is highly variable between the different syndromes, and also from one patient to another. These atypical symptoms are often isolated (i.e. without associated heartburn or regurgitation) making the diagnosis more difficult. In patients with atypical GERD manifestations, the success rate of acid suppressive therapy with PPI is rather low (if any) and mainly limited to the suppression of esophageal symptoms (heartburn, regurgitation and
PPIs long-term safety
In a non-life-threatening disorder like GERD, safety is a crucial issue. In this context, several concerns have been raised recently, suggesting possible PPI-related adverse events in long-term users. All these potential risks are not specific to GERD [113] but GERD is the most-frequent indication for long-term PPI use. Although PPIs are certainly over-prescribed, the magnitude of this misuse is difficult to quantify [114].
The risk of increased incidence of neoplasms under PPI therapy has been
Do we need more-potent antisecretory drugs in GERD?
In GERD, there is a strong, significant correlation between the degree of acid suppression provided by a given drug and its rate of efficacy [127], [128]. As previously indicated, the level of inhibition of gastric acidity achieved by a standard, once-daily dose of any available PPI is highly variable during the 24 h period, being maximal after meals while nocturnal acidity persists, especially during the second part of the night [128]. In addition, due to their pharmacological mechanism of
Conflict of interest statement
None declared.
Acknowledgements
Astra zeneca (research) Movetis (consulting)Given Imaging (consulting)Mauna kea Technologies (research support) Jansen Cilag (research).
References (142)
- et al.
Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study
Clin Gastroenterol Hepatol
(2005) - et al.
Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis
Gastroenterology
(1997) - et al.
Burden of digestive diseases in the United States part I: overall and upper gastrointestinal diseases
Gastroenterology
(2009) Controversies in long-term management of reflux disease
Baillière’s Best Pract Research Clin Gastroenterol
(2000)Strategies for medical management of reflux disease
Baillière’s Best Pract Research Clin Gastroenterol
(2000)- et al.
Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects
Gastroenterology
(1998) - et al.
Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough
Gastroenterology
(2002) - et al.
Proton pump inhibitors in GORD. An overview of their pharmacology, efficacy and safety
Pharm Res
(2009) - et al.
Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study
Am J Gastroenterol
(2003) - et al.
Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole
Dig Liver Dis
(2005)
Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis
Am J Gastroenterol
Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial
Am J Gastroenterol
Dysphagia in patients with erosive esophagitis: prevalence, severity, and response to proton pump inhibitor treatment
Clin Gastroenterol Hepatol
Effectiveness of proton pump inhibitors in non-erosive reflux disease
Clin Gastroenterol Hepatol
Rabeprazole in non erosive gastroesophageal reflux disease: a randomized placebo-controlled trial
Am J Gastroenterol
Intermittent and on-demand use of proton pump inhibitors in the management of symptomatic gastroesophageal reflux disease
Am J Gastroenterol
Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa
Gastroenterology
Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety
Am J Gastroenterol
What makes individuals with gastroesophageal reflux disease dissatisfied with their treatment?
Clin Gastroenterol Hepatol
The montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus
Am J Gastroenterol
Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease – an analysis based on the ProGERD initiative
Aliment Pharmacol Ther
Managing gastroesophageal reflux disease in primary care: the patient perspective
J Am Board Fam Pract
Symptom evaluation in reflux disease: workshop background, processes, terminology, recommendations, and discussion outputs
Gut
Medical treatments in the short term management of reflux esophagitis
Cochrane Database Syst Rev
Lansoprazole fast disintegrating tablet: a new formulation for an established proton pump inhibitor
Digestion
Proton pump inhibitors: better acid suppression when taken before a meal than without a meal
Aliment Pharmacol Ther
Esophageal acid exposure on proton pump inhibitors in unselected asymptomatic gastroesophageal reflux disease patients
J Clin Gastroenterol
Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms
Eur J Clin Pharmacol
Effect of proton pump inhibition on the gastric volume: assessed by magnetic resonance imaging
Aliment Pharmacol Ther
Effect of omeprazole 20 mg twice daily on duodenogastric and gastro-oesophageal bile reflux in barrett’s oesophagus
Gut
Rebound acid hypersecretion after long-term inhibition of gastric acid secretion
Aliment Pharmacol Ther
Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy
Gastroenterology
Dyspeptic symptoms development after discontinuation of a proton pump inhibitor: a double-blind placebo-controlled trial
Am J Gastroenterol
Editorial: just how “difficult” is it to withdraw PPI treatment?
Am J Gastroenterol
Impact of CYP2C19 polymorphisms on the clinical action of proton pump inhibitors (PPIs)
Eur J Clin Pharmacol
Omeprazole and CYP2C19 polymorphism: effects of long-term treatment on gastrin pepsinogen I, and chromogranin A in patients with acid related disorders
Aliment Pharmacol Ther
Systematic review: impaired drug absorption related to the co-administration of antisecretory therapy
Aliment Pharmacol Ther
Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel
Aliment Pharmacol Ther
A clinical trial comparing pantoprazole and esomeprazole to explore the concept of achieving ’complete remission’ in gastro-oesophageal reflux disease
Aliment Pharmacol Ther
Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta-analysis of long-term omeprazole trials
Aliment Pharmacol Ther
A systematic review of symptomatic outcomes used in oesophagitis drug therapy trials
Gut
Relationship between intragastric acid control and healing status in the treatment of moderate to severe erosive oesophagitis
Aliment Pharmacol Ther
A comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro-oesophageal reflux disease
Aliment Pharmacol Ther
The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole
Aliment Pharmacol Ther
Clinical practice. Gastroesophageal reflux disease
New Engl J Med
Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease
Cochrane Database Syst Rev
A multicenter, randomized, double-blind, 8-week comparative trial of low-dose esomeprazole (20 mg) and standard-dose omeprazole (20 mg) in patients with erosive esophagitis
Dig Dis Sci
A multicenter, randomized, double-blind, 8-week comparative trial of standard doses of esomeprazole (40 mg) and omeprazole (20 mg) for the treatment of erosive esophagitis
Dig Dis Sci
Systematic review: standard and double-dose proton pump inhibitors for the healing of severe erosive oesophagitis – a mixed treatment comparison of randomized controlled trials
Aliment Pharmacol Ther
A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study
Aliment Pharmacol Ther
Cited by (0)
- 1
Tel.: +33 240 083 306; fax: +33 240 083 168.